



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

614.ACUTE LYMPHOBLASTIC LEUKEMIAS: THERAPIES, EXCLUDING TRANSPLANTATION AND CELLULAR IMMUNOTHERAPIES**Efficacy of Bortezomib Combined with Hyper-CVAD in Adults with Relapsed Acute Lymphoblastic Leukemia or Positive Measurable Residual Disease**

Christian Omar Ramos Peñafiel^{1,2}, Daniela Pérez Sámano³, Adán Germán Gallardo-Rodríguez⁴, Irma Olarte Carrillo⁵, Camila Terreros Palacios⁶, Carlos Martínez Murillo, MD⁷, Gilberto Israel Barranco Lampón, MD⁸, Álvaro Cabrera García⁹, Humberto Baldemar Castellanos Sinco, MD¹⁰, Adolfo Martínez Tovar⁵

¹ Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Mexico City, Mexico

² Hematology Department, Regional Hospital of High Specialty of Ixtapaluca, Estado de México, Mexico., Mexico City, Mexico

³ 1. Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Mexico City, Mexico

⁴ Hematology Research Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Medicine Research Doctoral Program, Medical School, Instituto Politécnico Nacional, Mexico City, Mexico, Mexico City, Mexico

⁵ Molecular Laboratory, Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Mexico City, Mexico

⁶ Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Mexico City, Mexico

⁷ 1. Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Mexico, MEX

⁸ Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico., Mexico City, Mexico

⁹ 2. Hematology Department, Regional Hospital of High Specialty of Ixtapaluca, Estado de México, Mexico., Ixtapaluca, Estado De México, MEX

¹⁰ Hematology Department, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City Mexico., PACHUCA DE SOTO, Mexico

Background: Despite the advances in treating adult Acute Lymphoblastic Leukemia (ALL), relapses are among the most significant challenges to improving the prognosis. One of the tools that can predict bone marrow relapse, according to its positivity, is Measurable Residual Disease (MRD). Unfortunately, due to the high cost, access to innovative therapies is limited, so chemotherapy remains the most common treatment option. The combination of Bortezomib with Hyper-CVAD has already shown efficacy in patients with Multiple Myeloma. However, in patients with ALL, it is not yet proven. **Material and Methods:** A prospective cohort was carried out in patients with ALL who presented an +MRD or relapse and received treatment based on the combination of Bortezomib and Hyper-CVAD in two reference centers in Mexico City. **Results:** 20 cases with positive MRD were analyzed; 60% (n=12) became negative after the combination, 30% (n=6) persisted with a positive result, and 10% (n=2) passed away. Of the 43 individuals with bone marrow relapse, 43.5% (n=10) achieved a second complete remission (2CR), 34.8% (n=6) were refractory, and 21.7% (n=5) passed away. To integrate a second complete remission, 20% (n=2) achieved it in < 4 cycles, while 50% (n=5) required four cycles of treatment (2 cycles A and two cycles B), and 30% (n=3) required six cycles. **Conclusion:** The combination of Bortezomib with the increased Hyper-CVAD scheme showed better results in making MRD negative, suggesting that this combination can be incorporated into first-line strategies.

Keywords: Bortezomib; Chemotherapy; Acute Lymphoblastic Leukemia; Relapse; Measurable Residual Disease.

Disclosures No relevant conflicts of interest to declare.




Figure 1. Chart of survivability of patients with +MRD and relapse




Figure 2. Chart of survivability of patients according to the response to the combination of Hyper-CVAD + Bortezomib.

Figure 1

<https://doi.org/10.1182/blood-2023-173061>